NASDAQ$TWST
Twist Bioscience Corporation · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported record revenue again, with core business delivering strong results.
Twist Bioscience reported record revenue of $63.7 million for the third quarter of fiscal year 2023, a 14% increase compared to the same period in fiscal 2022. The company's core business, comprised of SynBio and NGS, delivered strong results. The company shipped products to approximately 2,200 customers and approximately 171,000 genes during the quarter.
- Total revenue for the third quarter of fiscal 2023 was $63.7 million, up from $56.1 million in the same period last year.
- Total orders received for the third quarter of fiscal 2023 were $63.8 million compared to $59.7 million for the same period of fiscal 2022.
- Net loss attributable to common stockholders for the third quarter of fiscal 2023 was $57.4 million, or $1.01 per share.
- As of June 30, 2023, the company had $357.1 million in cash, cash equivalents and investments.
Headline financials
Revenue & EPS history
Twist Bioscience · Revenue · Quarterly
$63.7M
Revenue by segment
Twist Bioscience · $218M total across 2 segments · Q3 2023
- NGS Applications$120M+23.7%55.0%
- DNA Synthesis & Protein$98M+22.5%45.0%
Forward guidance
Twist Bioscience provided financial guidance for the fourth quarter of fiscal 2023 and full fiscal year 2024.
Tailwinds
- Revenue for Q4 2023 is expected to be approximately $63 million to $64 million.
- Gross margin is expected to be approximately 36% for Q4 2023.
- Twist expects to exit fiscal 2024 with adjusted EBITDA breakeven for its core (SynBio, NGS) business in the fourth quarter.
- Operating expenses for DNA data storage are expected to be $40 million for fiscal year 2024.
- Fiscal year end cash is projected to be $220 million for fiscal year 2024.
Headwinds
- R&D expense is expected to be approximately $26 million for Q4 2023.
- SG&A expense is expected to be approximately $47 million for Q4 2023.
- Restructure expense is expected to be approximately $1 million for Q4 2023.
- Twist expects to be delayed in reaching its initial timeline in achieving adjusted EBITDA breakeven for its biopharma business exiting the fourth quarter of fiscal 2024.
- Revenue is expected to be approximately $241 million to $242 million for fiscal year 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.1%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+0.8%
Avg return
30 days after
47%
14 / 30 earnings
Positive
+29.7%
Q4 2023
Best reaction
-23.2%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -7.3% | -5.9% | +19.6% | |
| Q1 2026 | +13.8% | -5.9% | -10.2% | |
| Q4 2025 | -10.0% | -14.9% | +3.4% | |
| Q2 2025 | -8.5% | -16.9% | -20.8% | |
| Q1 2025 | +0.7% | -0.1% | -19.7% | |
| Q4 2024 | +12.0% | +14.5% | +20.9% | |
| Q3 2024 | -14.6% | -16.0% | -18.5% | |
| Q2 2024 | +28.9% | +34.9% | +31.1% | |
| Q1 2024 | +9.5% | +5.1% | +16.9% | |
| Q4 2023 | +29.7% | +24.9% | +81.5% | |
| Q3 2023 | +14.9% | +9.3% | +14.0% | |
| Q2 2023 | +3.6% | +2.1% | +26.0% | |
| Q1 2023 | -23.2% | -15.2% | -37.1% | |
| Q4 2022 | +0.8% | +0.5% | -0.6% | |
| Q3 2022 | +20.8% | +12.4% | -17.2% | |
| Q2 2022 | -9.9% | -16.3% | -12.6% | |
| Q1 2022 | -1.0% | +6.0% | -21.0% | |
| Q4 2021 | -12.6% | -14.1% | -22.4% | |
| Q3 2021 | -9.1% | -15.8% | -7.6% | |
| Q2 2021 | +6.2% | -9.4% | -12.4% | |
| Q1 2021 | -16.8% | -5.5% | -38.1% | |
| Q4 2020 | -9.9% | -0.8% | +44.3% | |
| Q3 2020 | -7.2% | -16.3% | -4.8% | |
| Q2 2020 | +5.1% | +4.6% | +0.7% | |
| Q1 2020 | +21.3% | +14.0% | +31.4% | |
| Q4 2019 | +4.6% | +5.8% | -15.5% | |
| Q3 2019 | -11.2% | -11.8% | -13.9% | |
| Q2 2019 | -9.9% | -9.7% | -3.9% | |
| Q1 2019 | -9.2% | -11.8% | -6.9% | |
| Q4 2018 | -9.2% | -9.4% | +18.6% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro